Toll Free: 1-888-928-9744

Immunomic Therapeutics, Inc. - Product Pipeline Review - 2014

Published: Oct, 2014 | Pages: 38 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Immunomic Therapeutics, Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Immunomic Therapeutics, Inc. - Product Pipeline Review - 2014', provides an overview of the Immunomic Therapeutics, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Immunomic Therapeutics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Immunomic Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Immunomic Therapeutics, Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Immunomic Therapeutics, Inc.'s pipeline products

Reasons to buy

- Evaluate Immunomic Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Immunomic Therapeutics, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Immunomic Therapeutics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Immunomic Therapeutics, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Immunomic Therapeutics, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Immunomic Therapeutics, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Immunomic Therapeutics, Inc. Snapshot 5
Immunomic Therapeutics, Inc. Overview 5
Key Information 5
Key Facts 5
Immunomic Therapeutics, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Immunomic Therapeutics, Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Combination Treatment Modalities 11
Pipeline Products - Out-Licensed Products 12
Out-Licensed Products/Combination Treatment Modalities 13
Immunomic Therapeutics, Inc. - Pipeline Products Glance 14
Immunomic Therapeutics, Inc. - Clinical Stage Pipeline Products 14
Phase II Products/Combination Treatment Modalities 14
Phase I Products/Combination Treatment Modalities 15
Immunomic Therapeutics, Inc. - Early Stage Pipeline Products 16
Preclinical Products/Combination Treatment Modalities 16
Discovery Products/Combination Treatment Modalities 17
Immunomic Therapeutics, Inc. - Drug Profiles 18
TriMix-DC Vaccine 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
Cell Therapy for HIV 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
HIV-LAMP-Vax 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
JRC-LAMP-Vax 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
LAMP-pp65 Dendritic Cell Vaccine + anti-IL-2R Monoclonal Antibody 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
MC-LAMP-Vax 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Td+pp65 DC Vaccine 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
ARA-LAMP-Vax 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
JCC-LAMP-Vax 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
LAMP + Antigen mRNA Vaccine 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Multi-LAMP-Vax 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Immunomic Therapeutics, Inc. - Pipeline Analysis 31
Immunomic Therapeutics, Inc. - Pipeline Products by Target 31
Immunomic Therapeutics, Inc. - Pipeline Products by Route of Administration 33
Immunomic Therapeutics, Inc. - Pipeline Products by Molecule Type 34
Immunomic Therapeutics, Inc. - Recent Pipeline Updates 35
Immunomic Therapeutics, Inc. - Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Appendix 37
Methodology 37
Coverage 37
Secondary Research 37
Primary Research 37
Expert Panel Validation 37
Contact Us 38
Disclaimer 38
List of Tables
Immunomic Therapeutics, Inc., Key Information 5
Immunomic Therapeutics, Inc., Key Facts 5
Immunomic Therapeutics, Inc. - Pipeline by Indication, 2014 8
Immunomic Therapeutics, Inc. - Pipeline by Stage of Development, 2014 9
Immunomic Therapeutics, Inc. - Monotherapy Products in Pipeline, 2014 10
Immunomic Therapeutics, Inc. - Combination Treatment Modalities in Pipeline, 2014 11
Immunomic Therapeutics, Inc. - Out-Licensed Products in Pipeline, 2014 12
Immunomic Therapeutics, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2014 13
Immunomic Therapeutics, Inc. - Phase II, 2014 14
Immunomic Therapeutics, Inc. - Phase I, 2014 15
Immunomic Therapeutics, Inc. - Preclinical, 2014 16
Immunomic Therapeutics, Inc. - Discovery, 2014 17
Immunomic Therapeutics, Inc. - Pipeline by Target, 2014 32
Immunomic Therapeutics, Inc. - Pipeline by Route of Administration, 2014 33
Immunomic Therapeutics, Inc. - Pipeline by Molecule Type, 2014 34
Immunomic Therapeutics, Inc. - Recent Pipeline Updates, 2014 35
Immunomic Therapeutics, Inc., Other Locations 36 



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify